Compared with the Dacarbazine-chemotherapy group, the Dabrafenib-treatment group not only improved the PFS of patients with BRAF V600E mutant metastatic MM but also increased the partial emission rate (PR) and complete remission (CR) rates. This evidence concerns the gene BRAF and Miyoshi myopathy.